Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (151-160 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|November 19, 2025
Editor's pick: Firefly BioKen Garber
Journal of the National Cancer Institute|December 31, 2010
Ready or not: personal tumor profiling tests take offKen Garber
Journal of the National Cancer Institute|October 12, 2010
A tale of two cells: discovering the origin of prostate cancerKen Garber
Nature Biotechnology|June 10, 2011
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritisKen Garber
Science (New York, N.Y.)|January 24, 2012
Autophagy. Explaining exerciseKen Garber
Nature Biotechnology|September 7, 2018
Alnylam launches era of RNAi drugsKen Garber
Science (New York, N.Y.)|May 13, 2006
Intellectual property. Decision on NFkappaB patent could have broad implications for biotechKen Garber
Journal of the National Cancer Institute|January 19, 2006
Momentum building for human epigenome projectKen Garber
Nature Biotechnology|December 11, 2007
Hepatitis C: staying the courseKen Garber
Journal of the National Cancer Institute|June 3, 2004
Debate rages over proteomic patternsKen Garber
Pageof 20

Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|November 19, 2025
Editor's pick: Firefly BioKen Garber
Journal of the National Cancer Institute|December 31, 2010
Ready or not: personal tumor profiling tests take offKen Garber
Journal of the National Cancer Institute|October 12, 2010
A tale of two cells: discovering the origin of prostate cancerKen Garber
Nature Biotechnology|June 10, 2011
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritisKen Garber
Science (New York, N.Y.)|January 24, 2012
Autophagy. Explaining exerciseKen Garber
Nature Biotechnology|September 7, 2018
Alnylam launches era of RNAi drugsKen Garber
Science (New York, N.Y.)|May 13, 2006
Intellectual property. Decision on NFkappaB patent could have broad implications for biotechKen Garber
Journal of the National Cancer Institute|January 19, 2006
Momentum building for human epigenome projectKen Garber
Nature Biotechnology|December 11, 2007
Hepatitis C: staying the courseKen Garber
Journal of the National Cancer Institute|June 3, 2004
Debate rages over proteomic patternsKen Garber
Pageof 20